Nccn ipi dlbcl: Free Evidence-Based oncology Scoring Tool

NCCN-IPIEnhanced DLBCL Prognostic Index

Demographics & Serology

Patient Age

LDH Level (Ratio to ULN)

Staging & Status

*Specific sites (Bone Marrow, CNS, Liver/GI tract, Lung) also count toward the extranodal point.

Awaiting Clinical Data

The NCCN-IPI is the current clinical standard for risk-stratifying patients with DLBCL in the modern rituximab era.

Risk Tiers

0-1: Low Risk
2-3: Low-Intermediate
4-5: High-Intermediate
>=6: High Risk

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Used prior to the initiation of frontline chemoimmunotherapy (e.g., R-CHOP, Pola-R-CHP) to counsel patients on long-term overall survival expectations.

Helps identify the highest risk cohort (High risk NCCN-IPI) that may be considered for frontline clinical trials or CAR-T evaluations if relapse occurs.

Clinical Pearls

Risk Groups (5-Year Overall Survival)

Risk Group	Points	5-Year OS	Implications
Low	0 - 1	96%	Excellent prognosis with standard R-CHOP.
Low-Intermediate	2 - 3	82%	Highly curable.
High-Intermediate	4 - 5	64%	Standard risk, but requires close post-treatment monitoring.
High	6 - 8	33%	Dismal outcomes with standard R-CHOP. Strong candidates for intensified regimens (e.g., Pola-R-CHP or trials) and rigorous CNS prophylaxis evaluation.

Last Comprehensive Review: 2026

NCCN-IPIEnhanced DLBCL Prognostic Index

Demographics & Serology

Patient Age

LDH Level (Ratio to ULN)

Staging & Status

*Specific sites (Bone Marrow, CNS, Liver/GI tract, Lung) also count toward the extranodal point.

Awaiting Clinical Data

The NCCN-IPI is the current clinical standard for risk-stratifying patients with DLBCL in the modern rituximab era.

Risk Tiers

0-1: Low Risk
2-3: Low-Intermediate
4-5: High-Intermediate
>=6: High Risk

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Used prior to the initiation of frontline chemoimmunotherapy (e.g., R-CHOP, Pola-R-CHP) to counsel patients on long-term overall survival expectations.

Helps identify the highest risk cohort (High risk NCCN-IPI) that may be considered for frontline clinical trials or CAR-T evaluations if relapse occurs.

Clinical Pearls

Risk Groups (5-Year Overall Survival)

Risk Group	Points	5-Year OS	Implications
Low	0 - 1	96%	Excellent prognosis with standard R-CHOP.
Low-Intermediate	2 - 3	82%	Highly curable.
High-Intermediate	4 - 5	64%	Standard risk, but requires close post-treatment monitoring.
High	6 - 8	33%	Dismal outcomes with standard R-CHOP. Strong candidates for intensified regimens (e.g., Pola-R-CHP or trials) and rigorous CNS prophylaxis evaluation.

Last Comprehensive Review: 2026

NCCN-IPI (DLBCL)

Demographics & Serology

Staging & Status

When to Use

When to Use

How it Works

Scoring Weights (Max 8 Points)

Clinical Pearls

Risk Groups (5-Year Overall Survival)

The Evidence

Key Reference

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Recent Journal Updates

NCCN-IPI (DLBCL)

Demographics & Serology

Staging & Status

When to Use

When to Use

How it Works

Scoring Weights (Max 8 Points)

Clinical Pearls

Risk Groups (5-Year Overall Survival)

The Evidence

Key Reference

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Recent Journal Updates